Microbiome-Derived Therapy Gets Orphan Drug Status for Hepatocellular Carcinoma
The Food and Drug Administration (FDA) has granted Orphan Drug designation to SFA001 (SFA Therapeutics) for the treatment of hepatocellular carcinoma (HCC).
All articles by Brian Park, PharmD
Investigational Farnesoid X Receptor Agonist Gets Fast Track Status for NASH
The FDA has granted Fast Track designation to TERN-101 (Terns Pharmaceuticals) for the treatment of non-alcoholic steatohepatitis.
-
Loading...
-
Loading...
Next post in Liver
